New Business Models Needed As Production Plateaus In China: PharmAsia Summit
This article was originally published in PharmAsia News
Executive Summary
Big Pharma executives expect China will continue to grow in importance for their companies, and about 40% said China will be one of the top three markets for the majority of companies, according to a new report unveiled at the PharmAsia Summit Shanghai.
You may also be interested in...
Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 2 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 1 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.